TARS Company Profile and Key Details

TARS has shown weak momentum, losing -6.09% over the past week and -2.74% over the past quarter, though year-to-date performance is down -13.37%. Short-term trend indicators are mixed aligned (SMA20 14.49%, SMA50 4.74%, SMA200 26.26%). The stock’s 14-day RSI is 63.77 (firm momentum), while the ATR of 4.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.0% below its high and over 97.01% above its low. Average 10-day trading volume of 734.96 thousand shares is below the 3-month average of 983.71 thousand, indicating normal recent market interest.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) closed at $78.23 USD, losing -$1.72 (-2.15%) from the previous close of $79.95. The stock is currently mid-range between its 52-week high and low $50.71 and $91.53. With a market capitalization of about $3.37 billion, Tarsus Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 1.02 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Tarsus Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bobak R. Azamian, the company employs approximately 370 people and listed since October 16, 2020. Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions.

Tarsus Pharmaceuticals, Inc. generated EPS of -$1.61 over the past year. Five-year average earnings growth is -3.8%. The latest quarter delivered EPS of -$0.43. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$2.67. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $105.00 to $87.00. The high target offers 34.22% upside. The low target suggests 11.21% downside. The mean target is $94.36. This offers 20.62% upside. Tarsus Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 124.23%. The prior quarter beat by -60.03%. Over the last six quarters, Apple has recorded several small beats. These include -7.25% in May 01, 2025.

Tarsus Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$40.03. This means the shares are trading below this model’s fair value.

Tarsus Pharmaceuticals, Inc. has 43.63 million shares outstanding. The public float is 32.11 million shares, elevated short interest at 13.69% of float. This equals 5.78 million shares. The short ratio is 4.26 days. Institutional investors hold 109.21% of the float. Insiders own 2.86%. Azamian Bobak R. holds 827.99 thousand shares, LINK WILLIAM J PHD has 106.79 thousand shares and Neervannan Seshadri has 78.53 thousand shares. Over the past six months, insider transactions show net selling. They sold 115.22 thousand shares across 25 transactions.

Tarsus Pharmaceuticals, Inc. trades at a P/E ratio of -71.73, slightly below the S&P 500 average, with a price-to-sales ratio of 5.55 and a price-to-book ratio of 9.79 trading at moderately above to book value. The P/FCF stands at 54.66, also above market averages.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares are down -13.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tarsus Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -71.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $65.82, suggesting -15.86% downside. Our AI forecast model points to short-term strength (11.62% over two weeks), a medium-term rise (74.0% over three months), and a longer-term gain (26.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Tarsus Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.62%, with price expected at $87.32 by September 29, 2026, within a range of $83.28 to $91.26 3-Month Outlook: Projected rise of 74.0%, reaching $136.12 by December 11, 2026, with a range of $131.84 to $140.70. 1-Year Outlook: Projected gain of 26.79%, with price at $99.19 by September 15, 2027, within a range of $96.22 to $102.65.